Form D · Biotechnology
Artiva Biotherapeutics, Inc.
San Diego, CA · CIK 0001817241
Offering snapshot reported Apr 5, 2021 · SEC filing
- Reported sold
- $120M Offering amount: $120M
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 5, 2021 | Initial | $120,000,001 | No comparison | Not reported | SEC filing |
| Jul 10, 2020 | Initial | $43,441,864 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-394686
Source: Form D, filed Apr 5, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Fred Aslan | Director, Executive |
| Jennifer Bush | Executive |
| Brian Daniels | Director |
| Thomas J. Farrell | Executive |
| Peter Flynn | Executive |
| Yong Jun Huh | Director |
| Yu Kyeong Hwang | Director |
| Bong Koh | Director |
| Jason Litten | Executive |
| Laura Stoppel | Director |
| Esther Van Den Boom | Executive |
| Yvonne Yamanaka | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4747 Executive Drive, Suite 1150
San Diego, CA, 92121
San Diego, CA, 92121